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 Microparticle-depleted blood plasma failed to coagulate in plastic cups 
 Polyethylene-carboxylate L-PPE:O nanocoatings were created by glow-discharge plasma 
 Hydroxyapatite particles, glass microbeads, and L-PPE:O coatings had anionic surfaces 
 Anionic surfaces induced burst coagulation of microparticle-depleted plasma via FXII 

















Biomaterials are frequently evaluated for pro-coagulant activity but usually in the presence of 
microparticles (MPs), cell-derived vesicles in blood plasma whose phospholipid surfaces allow 
coagulation factors to set up as functional assemblies. We tested the hypothesis that synthetic 
anionic surfaces can catalyze burst thrombin activation in human blood plasma in the absence of 
MPs. In a thromboelastography (TEG) assay with plastic sample cups and pins, recalcified human 
citrated platelet-poor plasma spontaneously burst-coagulated but with an unpredictable clotting 
time whereas plasma depleted of MPs by ultracentrifugation failed to coagulate. Coagulation of 
MP-depleted plasma was restored in a dose-dependent manner by glass microbeads, 
hydroxyapatite nanoparticles (HA NPs), and carboxylic acid-containing anionic nanocoatings  of 
TEG cups and pins (coated by glow-discharge plasma-polymerized ethylene containing oxygen, 
L-PPE:O with 4.4 and 6.8 atomic % [COOH]). Glass beads lost their pro-coagulant activity in MP-
depleted plasma after their surfaces were nanocoated with plasma-polymerized hexamethyl 
disiloxane (PP-HMDSO). In FXII-depleted MP-depleted plasma, glass microbeads failed to 
induce coagulation, however, FXIa was sufficient to induce coagulation in a dose-dependent 
manner, with no effect of glass beads. These data suggest that anionic surfaces of crystalline, 
organic, and amorphous solid synthetic materials catalyze explosive thrombin generation in MP-
depleted plasma by activating the FXII-dependent intrinsic contact pathway. The data also show 
that microparticles are pro-coagulant surfaces whose activity has been largely overlooked in many 
coagulation studies to-date. These results suggest a possible mechanism by which anionic 
biomaterial surfaces induce bone healing by contact osteogenesis, through fibrin clot formation in 
the absence of platelet activation.   
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Biomaterial-induced blood coagulation can lead to either therapeutic or adverse effects, 
therefore, the mechanisms governing biomaterial-induced coagulation should be thoroughly 
understood. Thromboelastography (TEG) is an in vitro assay used to study the effect of 
biomaterials on blood coagulation, and typically uses unmodified whole blood, citrated whole 
blood, or citrated blood plasma [1-5]. In the TEG assay, a liquid blood sample is deposited in a 
heated plastic cup and a plastic pin attached to a torsion wire is immersed in the sample. The cup 
oscillates at a fixed angle and when fibrin strands start to connect the cup and the pin, the torsion 
wire begins to rotate with the cup giving rise to a symmetric trace with an amplitude that is 
proportional to the viscoelastic clot tensile strength [6] (Fig 1). Thrombin activation dynamically 
parallels the TEG trace amplitude (parameter A) [7], meaning that explosive thrombin generation 
can be indirectly demonstrated by a sigmoidal curve which is usually accompanied by a sharp 
angle (≥30°) in the TEG trace (Fig. 1). Biomaterials and clotting factors introduced in the TEG 
assay can alter clotting time, , and TEG trace amplitude, with corresponding alterations in 
thrombin activation kinetics [2].  
Citrated platelet-poor plasma (PPP), like citrated whole blood, can be recalcified in vitro 
and will spontaneously burst coagulate in the TEG assay but with a variable clot initiation time 
[5]. PPP coagulates faster with more precise kinetics when the conventional plastic Cyrolite® TEG 
cup and pin are coated with anionic carboxylic acid (COOH)-rich nanolayers termed L-PPE:O 
(low-pressure plasma polymerized ethylene containing oxygen); these nanolayers consist of 
oxidized polyethylene and are generated by glow-discharge plasma-enhanced chemical vapor 
deposition (PECVD) [5]. It is important to distinguish between blood plasma and gaseous glow-
discharge plasma and in this text; hereafter, we shall mostly be referring to the former. Other 













and hydrophobic (PP-HMDSO), failed to accelerate PPP coagulation [5]. The mechanisms behind 
the pro-coagulant effect of L-PPE:O remain unclear. The purpose of this study was therefore to 
elucidate the mechanisms of anionic surface-induced PPP coagulation in the TEG assay. Our long-
term goal is to develop a novel functional bioassay for testing the potential for different 
biomaterials to influence burst thrombin activation in citrated plasma samples, using pooled 
qualified blood plasma as a standard, and plasma from distinct individuals for precision medicine.        
Citrated plasma is cleared of blood cells and most platelets by low-speed centrifugation but 
it still contains microparticles (MPs) and trace platelets (reviewed in [8, 9]). MPs (also called 
“platelet dust”, exosomes, extracellular vesicles) are phospholipid vesicles that are shed into the 
blood circulation from a variety of cell types including platelets, erythrocytes, leukocytes, and 
endothelial cells [10]. Ultracentrifugation can be used to collect MPs, and MPs from normal 
citrated plasma have modest pro-coagulant activity while MPs collected from individuals with 
pro-inflammatory states (sepsis, cardiac by-pass, kidney disease, heparin-induced 
thrombocytopenia) have relatively higher pro-coagulant activity [11-16]. As MPs are derived from 
multiple cell sources, it is important to note that MPs arising from different cell sources initiate 
and propagate coagulation through different mechanisms. Platelet-derived MPs (CD61+) display 
variable phosphatidyl serine (PS) content on their outer surface [13, 17]. PS is normally located 
on the inner cell membrane and upon platelet activation a flippase/scramblase transfers PS to the 
external membrane leaflet. PS carries a unique anionic carboxylic acid charge group that serves as 
an essential docking site that tethers and orients the calcium-binding γ-carboxyglutamic acid (gla) 
domain of key coagulation factors (FVII, FIX, FX, FII/prothrombin, Protein C), so that their active 
sites and sessile bonds are at an optimal distance from the plasma membrane (i.e., 52 to 90 Å) [18, 
19]. Granulocyte- (CD66b+) and monocyte-derived (CD14+) MPs express different levels of 













domain serine protease that when complexed with TF directly activates FIX and FX to create 
tenase and prothrombinase, respectively [20, 21]. To summarize, MPs in normal blood plasma 
have features that facilitate coagulation by contributing trace PS+ binding sites for cooperative 
assembly of tenase, prothrombinase, and prothrombin, and potentially trace TF [8, 13]. 
In order to test the hypothesis that MPs are required to initiate burst coagulate of PPP in 
the TEG assay, we used ultracentrifugation (136,000xg) to produce MP-depleted and MP-enriched 
plasma. Samples were recalcified and allowed to coagulate in the TEG assay using commercially 
supplied Cyrolite® plastic cups and pins. Our first experiments showed that PPP and PPP enriched 
2-fold for MPs spontaneously burst-coagulated, while MP-depleted plasma failed to coagulate in 
the plastic TEG cups. We then tested the hypothesis that synthetic anionic surfaces stimulate 
coagulation of PPP, and are necessary and sufficient to induce coagulation of MP-depleted plasma. 
Our results showed that MP-depleted plasma burst coagulated solely in contact with anionic 
surfaces, and that the effect was sensitive to the anion charge density. We also provide evidence 
using FXII-depleted plasma spiked with FXIa that anionic surfaces induce burst coagulation of 

















Plastic TEG cups and pins made of Cyrolite®, a methacrylate-based polymer, were purchased 
from Haemonetics Corporation (IN, USA) or Hemoscope (IN, USA). Other reagents included 10 
µm-diameter carboxylated CML latex beads at 4% w/v (Life Technologies, Cedarlane, ON, 
Canada, Product No. C37259, Lot No. 1071765 with 6.8x108 COOH groups per particle), 10 µm 
diameter dark red latex beads at 2% w/v (Sigma-Aldrich, Oakville, ON, Canada, Product No. 
61946), 10 µm diameter borosilicate glass beads (SPHERICEL® Hollow 10 µm Glass Spheres, 
Grade 110P8, Matweb), synthetic HA nanoparticle rods of 40 nm x 9 nm created with CTAB and 
IGEPAL (2.03 Ca/P ratio) [22], and CaCl2 (Sigma-Aldrich, Oakville, ON, Canada, Product No. 
C5670 dihydrate or C7902 anhydrous) to prepare 200 mM CaCl2 (osmolality of 490 to 510 
mOsm). The 4% w/v latex bead, CML bead, and glass microbead suspensions were generated at 
2.5 mg/mL in 200 mM CaCl2 to obtain an average 4.25±0.75 million beads per mL 200 mM CaCl2 
as verified with a Countess Automated cell counter (Invitrogen, Thermo-Fisher, Canada). HA 
nanoparticles were suspended in ddH20 at 0.25, 2.5, and 25 mg/mL and characterized for zeta 
potential in 0.01 M NaCl solution pH 7.0 in triplicate. 
2.2. PECVD thin film coatings of TEG cups and pins and glass beads 
The inner surface of the TEG cups and outer surface of the TEG pins were coated using PECVD 
to make ~200 nm thick nanocoatings with hydrophobic character (PP-HMDSO, plasma-
polymerized hexamethyldisiloxane), or hydrophilic anionic character (L-PPE:O), at distinct 
oxygen/ethylene gas flow ratios, R≡ O2/C2H4 of 0.025, 0.05, and 0.075) as previously described 
[5]. Briefly, TEG cups and pins were placed in custom aluminum holders on the lower plate 













was filled with a flowing gas mixture of ethylene (99.5%) and 10% oxygen/90% argon gas mixture 
(for L-PPE:O), or pure HMDSO (99.7%) vapor for (PP-HMDSO) while controlling the applied 
13.56 MHz radio-frequency power (ca. 10 Watts) and operating pressure (ca 600 mTorr) to create 
the ~200 nm thick coatings. Small pieces of single-crystal silicon (c-Si) wafer were placed on the 
aluminum holders during deposition runs as test surfaces for water contact angle measurements. 
Glass beads (500 µm diameter, Zymogen, QC, Canada) were also coated as a single bead layer 
with PP-HMDSO using the same parameters, then part-way through the coating, the glass beads 
were moved one by one and the PECVD treatment repeated so that all bead surfaces were coated.  
2.3. Characterization of coatings 
X-ray photoelectron spectroscopy (XPS)  
The TEG cups and L-PPE:O-modified TEG cup surfaces were characterized by high resolution X-
ray Photoelectron Spectroscopy (HR XPS) (VG ESCALAB 3MkII instrument, using non-
monochromatic Mg K radiation) directly on the bottom of the TEG cup [5]. Functional 
concentrations were determined using Avantage v4.12 software (Thermo Electron Corp.) by 
integration of the area under specific sub-peaks following subtraction of a Shirley-type 
background. O1s was fitted with two peaks (O=C (532.4 eV) and O-C (533.9 eV) while C1s was 
fitted with 5 peaks, A, B, C (285.0, C-C, C=C; 285.7, C-COOR; 286.6 eV, C-OR; respectively), 
peak D (C=O, 287.9 eV) and E (COOR, 289.2 eV). The oxygen content of Cyrolite® and PP-
HMDSO thin films was previously reported [5]. The carboxylic acid/ester content of the L-PPE:O 
surfaces was quantified by calculating the area under the HR-XPS C1s peak at 289.2 eV (Avantage 
v4.12 software). COOR content of CML beads was determined using the same approach. Calcium 
content of borosilicate glass beads, and surface character of 500 µm glass bead surfaces before and 













Contact angle goniometry (CAG)  
CAG measurements determine the angle between a surface and the tangent made with it by a small 
water droplet deposited on the surface. CAG using water gives a rough indicator of surface 
wettability. Note that hydrophilicity is not a precise notion, because CA depends not only on 
chemistry, but also on surface morphology (roughness). Generally, if the WCA is >90°, the solid 
surface is considered hydrophobic. CAG measurements were carried out with a dedicated 
goniometer (Ramé-Hart, Inc.) on a flat part of the TEG cup (Cyrolite®), or on a PECVD deposit 
made on a piece of c-Si wafer, and reproducibility was verified by repeating the procedure 3 times.    
2.4 Thromboelastography assays.  
Assays were carried out in three tandem TEG 5000 thromboelastograph instruments (Haemonetics 
Corporation, Niles, IL, USA), permitting the simultaneous analysis of six samples, or a single TEG 
5000 analyzer (FXII-depleted plasma assays). Citrated PPP containing 3.2% w/v citrate 
(CRYOcheck®, Catalog number: CNN-15, lot# A1104, Precision BioLogic, Dartmouth, Nova 
Scotia, Canada, confirmatory experiments with lot# A1151) collected by apheresis from consented 
healthy human donors and pooled, was characterized as containing 2.90 or 3.34 g/L fibrinogen, 
and from 92% to 118% FII, FV, FVII, VIII, FIX, FX, FXI, and FXII (according to the Certificates 
of Analysis), and platelet counts less than 1 million per mL (personal communication Stephen 
Yorke, Technical Support, Precision BioLogic). Plasma was received frozen on dry ice in 1.5 mL 
aliquots, was stored at -80ºC, and thawed at 37ºC for 5 minutes prior to use. TEG instruments were 
verified by e-tests prior to each experiment. MP-depleted plasma was generated as follows: 1 mL 
PPP was ultra-centrifuged for 30 minutes at 50,000 rpm (136,000xg) at 4°C in a fixed angle rotor 
TLA-110 (Optima Max-E Beckman Ultracentrifuge) in 1.5 mL Microfuge® polyallomer tubes 













recovered avoiding any floating lipids, while MP-enriched plasma consisted of the resulting pellet 
containing MPs resuspended by vortexing in the remaining 0.5 mL PPP. TEG assays in unmodified 
and PECVD-modified TEG cups were run by depositing 20 L of 200 mM CaCl2 in the TEG cup, 
followed by 340 L of citrated platelet-poor plasma (PPP), MP-enriched, or MP-depleted plasma. 
Other assays were performed with 20 L of 200 mM CaCl2 containing 2.5 mg/mL microbeads and 
340 L plasma, or 20 L of 200 mM CaCl2, 20 L of ddH20 with or without HA NPs (0.25, 2.5 
or 25 mg/mL) and 320 L plasma. The volume of plasma in the TEG cups was kept constant 
regardless of the number and volume of substances added, either 320 µL (HA NPs) or 340 µL (all 
other conditions) (Table 1).  Microbead and HA NP suspensions were vortexed immediately prior 
to pipetting into the TEG cup. TEG assays were also carried out using citrated FXII-depleted 
plasma (catalog number FDP12-10, Lot D12-34, pooled PPP immunoadsorbed to deplete FXII to 
<1%, HEPES buffered, frozen; Precision BioLogic). Plasma was thawed at 37°C, depleted of MPs 
by ultracentrifuging at 50,000xrpm as described above, then the coagulation assay performed by 
pipetting into the TEG cup: 20 L of 200 mM CaCl2 ± 2.5 mg/mL glass microbeads, 20 L of 
ddH20, or 20 L FXIa (Haematologic Technologies, VT, USA; diluted 1:500, 1:5000 or 1:12,500 
in ddH20 from a 591 U/mg, 5.1 mg/mL stock), then 320 L FXII-depleted MP-depleted plasma.  
2.5 Environmental Scanning Electron Microscopy (ESEM) 
MPs were pelleted by ultra-centrifugation (136,000xg, 30 minutes, 4°C), then re-suspended in 100 
µL supernatant by 20 seconds of vortex mixing, fixed by adding excess 2% glutaraldehyde/0.1 M 
sodium cacodylate pH 7.3, washed twice in ddH20 (ultra-centrifuging each time), then transferred 
to an ESEM stage and imaged under high vacuum in a Quanta 200 field-emission gun (FEG) 
environmental scanning electron microscope (ESEM).  PPP and MP-depleted plasma clots were 













2% glutaraldehyde/0.1 M sodium cacodylate pH 7.3, washed 3 times 5 min. in ddH20, dehydrated 
in graded ethanol series followed by amyl acetate/ethanol, submitted the Facility for Electron 
Microscopy Research (McGill University, Montreal, Canada) for critical-point drying, then 
submitted to the following gold sputtering parameters: 80 seconds (<8 nm thickness), pump 
pressure 0.08 mBar, sputter current: 30 mAmp, table position: at 30 mm target to sample distance, 
and analyzed under high vacuum mode at 10 kV by ESEM.   
2.6 Statistical Analyses       
Data are presented as mean (marker) ± standard error (bars) ± standard deviation of the mean 
(whiskers). Differences in TEG parameters R, α (alpha) and MA were evaluated using the General 
Linear Model with an Unequal N Honest Significant Differences (HSD) post-hoc test (Statistica 
v12, Tulsa, OK, USA). Sample numbers for PPP samples were as follows: Cyrolite TEG cup 
N=14, HMDSO-coated TEG cups N=6, latex beads N=3, carboxylated CML latex beads N=6, 
glass beads N=8, HA at 25 mg/mL N=5, L-PPE:O coated TEG cups at R=0.075 N=5, MP-enriched 
plasma N=10. Sample numbers for MP-depleted plasma were as follows: Cyrolite TEG cup N=11, 
HMDSO coating N=4, latex beads, N=4, carboxylated CML latex beads N=6, glass microbeads 
N=7, HA NPs N=4, L-PPE:O coating (R=0.075) N=8. MP-enriched PPP N=9. The level of 
significance was set at p = 0.05.  
 
3. Results   
MPs pelleted from citrated PPP by ultracentrifugation and fixed in glutaraldehyde formed 
circular sub-micron aggregated structures (Fig. 2A). In the TEG assay with standard plastic cups 













kinetics proportional to MP concentration, whereas MP-depleted plasma failed to coagulate (Fig. 
2B).    
TEG cups and pins were modified by PECVD to have surfaces with different levels of 
[COOH] by step-wise increases in the O2/C2H2 gas flow ratio (R=0.025, 0.05, and 0.075); the 
resulting L-PPE:O surfaces had increasing wettability as shown by a progressive decrease in water 
contact angle (WCA 64°, 51° and 45°, respectively, Table 2), along with a progressive increase in 
oxygen content, [O] ([O] = 14.3, 24.4, and 29.8 atomic % (at%)). L-PPE:O R=0.05 had [O] 
comparable to that of Cyrolite ([O] = 22.3 at%, Table 3). It is important to note that one L-PPE:O 
surface with the lowest oxygen level had zero [COOH] content, while the other two L-PPE:O 
surfaces had 4.4, and 6.8 at% [COOH}, respectively (peak E, Table 4, Fig. 3). Uncoated Cyrolite 
was more hydrophobic (WCA 77°) and HMDSO-coated surfaces were hydrophobic (WCA 98°, 
Table 2), which is consistent with a lack of free hydroxyl (OH) or carboxylic acid (COOH) groups 
in the methacrylate-based Cyrolite or in PP-HMDSO organosilicone film coatings (Table 4) [5].   
The anionic character of L-PPE:O thin layers with 6.8 at% [COOH] immersed in water has 
been previously established (-15 V surface potential) [5]. Another experimental anionic material 
consisted of HA NPs with a Ca/P ratio of 2.03 [22]. HA NPs showed a zeta potential of -6.19 ± 
0.83 mV in 10 mM NaCl of pH=7.0. Borosilicate glass (SiO) has an anionic surface in aqueous 
solution [23] that promotes the FXII-dependent contact pathway [24]. As calcium is  essential for 
coagulation, it is interesting to note that the HA NPs showed a structure of Ca10(PO4)6(OH)2 [22], 
and according to XPS analyses, glass microbeads showed a calcium content of 2.4 at% Ca2p3 
(peak signal at 248.3 eV).  
PPP showed an average 16 ±6 minute clot initiation time in standard plastic Cyrolite TEG 













optimal stimulation at 2 mg/mL (parameter R, Fig. 4A). At the optimal concentration, all three 
anionic surfaces (2 mg/mL HA NPs, 0.2 mg/mL glass beads, L-PPE:O with 6.8 at% [COO] 
shortened PPP coagulation time to precisely 9±1 minutes (p<0.05 to 0.01 vs all other surfaces,  
Fig. 4B). Hydrophobic surfaces (HMDSO coatings, latex beads), and mixed 
hydrophobic/hydrophilic surfaces (CML beads), delayed the average PPP clot initiation time to 
between 19 and 23 minutes (black boxes, Fig. 4B). PPP burst-coagulated with an average alpha 
38°±16° that was depressed by hydrophobic surfaces to between 23° and 29°, and amplified by 
anionic surfaces to have consistently high values of 62°±4° (glass beads), 60°±4° (HA NPs), 
and 53°±6° (L-PPE:O) (p<0.05 to 0.001 vs all other surfaces, open boxes, Fig. 4B). The maximal 
amplitude (MA) value, which reflects clot tensile strength was not significantly altered by any of 
the surfaces (grey boxes, Fig. 4). To summarize, these data showed that all three anionic surfaces 
promoted a faster and more reproducible burst coagulation of PPP which contains MPs and trace 
platelets (i.e., less than 1 million platelets per mL versus 143 to 450 million platelets per mL in 
normal human whole blood [25]).  
Remarkably, synthetic anionic surfaces restored burst coagulation of MP-depleted plasma 
in a dose-dependent manner. L-PPE:O nano-coatings initiated coagulation according to carboxylic 
acid content, with an average clotting time of 18 minutes and  = 32° for 4.4 at% [COO], and a 
more rapid clotting time of 11 minutes and  = 48° for 6.8 at% [COO] (Fig. 5A). Most 
importantly, L-PPE:O surfaces devoid of [COO] failed to induce coagulation of MP-depleted 
plasma (R=0.025, Fig. 5A). HA NPs induced burst coagulation of MP-depleted plasma at 2 mg/mL 
(but not lower concentrations), with a relatively slower clotting time of 24 minutes and  37° 
(Fig. 5). Glass microbeads induced burst coagulation of MP-depleted plasma at 0.2 mg/mL, with 













no longer induced coagulation of MP-depleted plasma, ruling out surface curvature as a factor 
(data not shown; Table 5). Among all anionic surfaces, L-PPE:O coatings with 6.8 at% [COO] 
induced the shortest clotting time (11 minutes), and highest α (48°) of MP-depleted plasma (Fig. 
6A). Clot tensile strength was similar for PPP, E-PPP, and MP-depleted plasma induced to 
coagulate with anionic surfaces (Fig. 5B). To summarize, these data showed that organic (L-
PPE:O), crystalline (HA NPs), and amorphous solid (glass microbead) synthetic anionic surfaces 
had a similar in vitro pro-coagulant activity as MPs.      
Given that anionic surfaces activate FXII and induce the contact pathway, we evaluated 
the potential role of the contact pathway in coagulation of MP-depleted plasma. We used used 
FXIa, the factor immediately downstream of FXIIa, to by-pass FXII and initiate coagulation in 
FXII-depleted, MP-depleted plasma. As expected, calcium or calcium with glass beads failed to 
induce coagulation (Fig. 6B). FXIa stimulated a dose-dependent burst coagulation of FXII-
depleted plasma, MP-depleted plasma, with no effect of glass beads (Fig. 6B). These data showed 
that activation of the contact pathway is sufficient to induce burst coagulation of MP-depleted 
plasma. 
Fibrin clot fiber structure was examined at high-magnification in PPP and MP-depleted 
plasma coagulated in the presence of glass microbeads. A meshwork of fibrin fibers enveloped the 
glass beads (Fig. 7A & D). Thick and thin fibrin fibers adhered to the glass beads in both PPP clots 
and MP-depleted plasma clots (Fig. 7A-B vs 7D-E).  Fibrin networks formed in PPP and MP-
depleted plasma in the presence of glass beads had a similar structure (Fig. 7C vs 7F), except for 
the presence of sub-micron spherical aggregates near the surface of the PPP clot that could 














4. Discussion  
This study has generated new knowledge of the inherent potential for synthetic anionic 
surfaces to initiate and propagate burst coagulation of citrated plasma. Our data reveal a previously 
unsuspected ability of calcium phosphate minerals, glass beads, and carboxylated surfaces to 
substitute for anionic phospholipid surfaces normally provided by MPs in platelet-poor plasma 
[16]. Seminal experiments by Ratnoff showed that anionic glass surfaces activate the contact 
pathway in blood plasma through FXII [28]. More recently, it was suggested that hydrophobic 
surfaces also have the potential to activate the contact pathway through factor XII activation [24], 
however these previous studies were carried out using PPP [29] which also contains MPs. In the 
present study, we showed that MPs were necessary and sufficient to induce burst coagulation of 
recalcified citrated plasma. These results are consistent with the findings of Wang et al [27] 
showing that murine neutrophil-shed MPs stimulate thrombin generation through a FXII-
dependent pathway. We furthermore showed that hydrophobic surfaces and polar uncharged 
surfaces (Latex beads, CML beads, L-PPE:O R=0.025 with 0 at.% [COO]) failed to accelerate 
coagulation of PPP, and also failed to induce coagulation of MP-depleted plasma.  Anionic 
surfaces could substitute for MPs in initiating coagulation of MP-depleted plasma, provided that 
the contact pathway was initiated (i.e., FXIa). The resulting fibrin clot structure was similar for 
PPP and MP-depleted plasma fibrin clots. From the collective data, we conclude that synthetic 
anionic surfaces analyzed in this study induced burst coagulation of MP-depleted plasma with 
kinetics related to their rates of FXIIa and FXIa generation.  
Data generated in this study and others suggest that MP surfaces present in normal pooled 
human citrated blood plasma have a similar ability to stimulate the contact pathway as a variety of 













important because many historical coagulation experiments have over-looked MPs as contributors 
to contact-activation in samples that are often citrated PPP. These data add new information to 
growing evidence that MPs participate in mediating large thrombus formation, by generating FXII 
at a distance from cell surfaces . The effect could be more relevant in context of stagnant blood 
flow such as a compressed wound, because otherwise the MPs would be carried away by the 
circulation from the bleeding site.  
Numerous studies have shown that FXII, the first enzyme of the contact pathway, is 
activated by anions such as poly-phosphates liberated from platelets, by glass, ellagic acid, kaolin, 
carboxylated anionic polystyrene nanoparticles, long-chain non-saturated fatty acids (stearate), 
dextran sulfate, as well as more recently MPs with surface-exposed PS [1, 16, 24, 27, 28, 31-35]. 
During the initiation phase of the contact pathway, anionic surfaces adsorb FXII, as well as high 
molecular weight kininogen (HMWK), a cofactor that circulates as HMWK-prekallikrein (PK) 
and HMWK-FXI dimer complexes [34, 36, 37]. It is believed that surface-adsorbed FXII 
undergoes allosteric changes that expose the active site of the zymogen without proteolytic 
cleavage, which permits FXII to activate PK to kallikrein [26]. This model is supported by the 
observation that in FXII-deficient plasma, anionic surfaces cannot convert PK to kallikrein [38]. 
FXII adsorbed to anionic surfaces renders FXII 50-times more susceptible to proteolytic 
activation, notably by kallikrein in the presence of HMWK . This sets up a reciprocal FXIIa and 
kallikrein activation on the anionic surface as well as FXIIa activation of FXI/HMWK to 
FXIa/HMWK [38]. All of these steps can occur in the absence of calcium [37]. When contact 
activation takes place in the presence of calcium, the common pathway is directly launched: FXIa 
converts FIX to FIXa (tenase) by 2 cleavages [41], then FIX converts FX to FXa (prothrombinase), 













The common pathway reactions are spatially coordinated due to conserved gla domains in 
FIX, FX and FII that allow the factors to become concentrated on PS+ membranes. In previous 
studies, platelet-derived poly-phosphate, anionic carboxylated nanobeads, and kaolin accelerated 
coagulation of PPP in a dose-dependent manner at 0.02 to 0.5 mg/mL [31, 32, 42], similar 
concentrations as the glass microbeads and HA NPs analyzed in this study. It is noteworthy that 
all three of these surfaces stimulated PPP coagulation with a kinetics very similar to that reported 
by Fletcher et al. for kaolin-activated human pooled PPP (R=9.4 minutes, =52°, MA=24.6 mm) 
[42]. This reproducible 9 minute delay for contact-activated PPP to coagulate was simulated by 
adding 0.03 U/mL FXIa to MP-depleted, FXII-depleted plasma, and shortened by adding 0.3 U 
FXIa, suggesting that the rate of FXII is a limiting factor in the reproducible maximal kinetics of 
coagulation in the TEG assay. Another factor in the time delay could be related to the time required 
for initial thrombin levels during the initiation phase, or “kindling phase”, to activate cofactors 
FVIII and FV that are missing a gla domain [43]. After contact pathway activation of PPP, tenase, 
prothrombinase and prothrombin can concentrate on the surface of PS+ MPs leading to burst 
coagulation. Collective data indicate that HA NPs, glass beads and L-PPE:O activated the contact 
pathway; however this still begs the question, where did tenase, prothrombinase, and prothrombin 
bind in MP-depleted plasma induced to coagulate by glass beads, HA NPs and L-PPE:O containing 
[COO]?   
Burst coagulation through the intrinsic pathway depends on a battery of coagulation factors 
that form multi-subunit assemblies, and PS plays an essential role. Among the major phospholipids 
phosphatidyl choline, phosphatidyl ethanolamine, and PS, PS is the only anionic lipid that can 
effectively mediate coagulation factor assembly although lysophosphatidyl serine can also 













charged carboxyl group at neutral pH (pKa 3.6) [45]. It is believed that a single PS molecule 
complexes with the gla domain of prothromin through the PS carboxylate group and two calcium 
bridging ions embedded in the gla domain while phosphates of PS and surrounding lipids serve to 
stabilize and orient the rest of the gla domain so that the active site presents at the optimal distance 
from the lipid membrane surface [44]. The PS carboxylate group therefore mediates gla domain 
tethering. 
Gla domains carry a cluster of glutamic acid residues bearing extra carboxyl groups 
through a Vitamin K-dependent post-translational modification. The highly charged gla domain is 
folded in a tight complex with multiple calcium ions to form a binding site that latches the factor 
in an optimal orientation onto lipid membrane surfaces rich in anionic PS [19, 44]. Active thrombin 
is generated by two thrombinase cleavages, one that cleaves inside the thrombin enzyme and 
another that splits thrombin from the F1.2 gla domain-containing fragment [46]. According to the 
current modified “waterfall” model of coagulation factor activation, low levels of thrombin 
generated during the initiation phase feed-back activate co-factors lacking a gla domain: FXI, FV 
and FVIII [47-49], although the ability of thrombin to activate FXI in plasma is under debate [50]. 
Activation of FVa is a crucial step because FXa prothrombinase activity is exponentially ramped 
up by recruitment of FVa which can also complex with the gla domain of prothrombin [48, 51]. 
This sequence of events leads to explosive thrombin generation in the propagation phase, all 
provided that binding sites such as PS are available to concentrate the gla domain factors in the 
same physical space [52].   
The active site of FVIIa bound to TF is estimated to occur at 52 to 76 Å from the plasma 
membrane surface. Ohkubo [19] estimated that insertion of the gla domain into the anionic lipid 
membrane is required for optimal alignment of the catalytic domains of coagulation factors. Both 













gla domains become optimally aligned when the  loop of the gla domain inserts into anionic 
membranes to a depth of around 5 to 10 Å. In this model, the calcium ions complexed with gla 
residues are close to the phosphate groups of lysophosphatides [19]. The  loop may have some 
capacity to interact with carboxylic acid groups in L-PPE:O. The  loop has no capacity to 
penetrate the smooth glass or HA NP surfaces, although is relevant to note that calcium ions can 
complex with PO4
3 and mediate the binding of a variety of gla-domain proteins with bone mineral 
phosphates including SPARC (osteonectin), matrix gla protein (MGP), and gla-rich protein (GRP) 
[54, 55]. It is therefore possible that gla domain coagulation factors could concentrate on the 
surfaces of HA NPs through mechanisms that remain to be elucidated. However, given that XIa 
alone could stimulate burst coagulation of MP-depleted plasma in the absence of exogenous 
anionic surfaces, it is most probable that residual MPs remained in our MP-depleted plasma and 
provided sufficient phosphatidyl serine groups and/or their tissue factor to mediate gla domain 
factor assembly. Future experiments are warranted to clarify these physical interactions and 
potential role of TF.  
Our study provides a new type of advanced prothrombin time (APTT) test, where in the 
TEG assay the kinetics of spontaneous clot initiation by trace MPs in PPP could be out-competed 
by 0.2 mg/mL glass microbeads to initiate a very precise clot initiation time in the TEG assay. The 
glass microbead TEG assay could therefore be used with PPP or MP-depleted plasma to compare 
the relative effect of biomaterials, activators and inhibitors on the intrinsic coagulation cascade. 
Future tests will show whether the glass microbead TEG assay will give similar results with 
clinical samples from subjects with different inflammatory states, distinct anticoagulant therapies 













Findings in this study have some clinical relevance. The pro-coagulant activity of calcium 
phosphate crystals in vivo could serve a beneficial function of ensuring that thrombin is generated 
at a fractured bone mineral surface, with ensuing fibrin formation connecting the fracture with the 
hematoma. Shiu et al [57] have argued that fibrin clot formation plays a key role in contact 
osteogenesis, by serving a scaffold for continuous recruitment of osteogenic cells for direct bone 
deposition on an implant surface. With this notion, and the data presented here, we propose that 
some anionic particle-containing biomaterials could be osteogenic in vivo by virtue of their initial 
pro-thrombogenic activity at the time of implantation. Pro-coagulant activity of anionic particles 
wear debris could also have implications in certain painful disease states such as heterotopic 
ossification which occurs through unexplained mechanisms in soft tissues around healing 
polytraumatic bone fractures, and in osteoarthritis [58]. These data provide a new understanding 
of biomaterial-blood interactions and the potential impact on human health.  The implication is 
that bone void fillers with anionic surfaces could activate the coagulation cascade to promote fibrin 
fibers to connect with the material and provide a scaffold for inward cell migration, because HA 
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Figure 1: Kinetics of fibrin fiber formation influence different stages of the TEG trace. Panel (A) 
shows stages of coagulation and fibrin fiber formation in the TEG assay in a representative trace 
of recalcified citrated platelet-poor blood plasma sample. Panel (B) depicts the sequential process 
of fibrin polymerization after thrombin-induced cleavage of telopeptides A and B from the 
fibrinogen hexamer precursor. Pro-coagulant activity can be demonstrated by a shorter clotting 
time (R), shorter time to attain 20 mm amplitude (K), and high alpha (, angle, red lines).   
 
Figure 2. Ultrastructure of the pelleted formalin-fixed MP fraction by ESEM imaging (A) and 
representative TEG traces of recalcified citrated PPP, MP-enriched, and MP-depleted plasma 
permitted to coagulate spontaneously in the Cyrolite plastic TEG cup and pin (B).  PPP and MP-
enriched plasma coagulated spontaneously but MP-depleted plasma failed to coagulate.  
 
Figure 3.  High resolution X-ray photon spectroscopy (C1s and O1s) spectra for L-PPE:O 
coatings: a) R= 0.025,  b) R= 0.050,and c) R= 0.075. Peak E representing the carboxylic acid 














Figure 4. TEG assay of PPP coagulation in the presence of different surfaces. Coagulation was 
accelerated by synthetic anionic surfaces and delayed by hydrophobic surfaces, relative to the 
conventional Cyrolite TEG cup and pin surfaces.  (A) HA NPs accelerated PPP coagulation in a 
dose-dependent manner. These data are the first to our knowledge to show that hydroxyapatite is 
a pro-coagulant surface that accelerates PPP coagulation.  N=4 each condition except 25 mg/mL 
was N=5. (B) Anionic surfaces provided by glass beads and L-PPE:O (R= 0.075, 6.8 atomic % 
[COO]) stimulated PPP coagulation while hydrophobic (CYR, H, LB) and hydrophilic 













R: clotting time; (alpha): angle of burst coagulation; CYR: Cyrolite® TEG cups and pins; H: 
PP-HMDSO-coated TEG cups and pins; LB: latex beads; CB*: CML carboxylated latex beads 
that only carry a net negative charge at alkaline pH (pH 10); GB: Glass microbeads; PPEO: R= 
0.075 L-PPE:O-coated TEG cups and pins. Sample characteristics: See Table 1.    
 
Figure 5. TEG assay of MP-depleted plasma coagulation in the presence of different surfaces. 
Anionic surfaces accelerated coagulation of MP-depleted plasma while hydrophilic surfaces 













Cyrolite TEG cup. (A) All L-PPE:O nanocoatings have oxygen content but only those with 
[COO] content, and HA NPs at the highest concentration, restored burst coagulation of MP-
depleted plasma. (B) Glass microbeads, HA NPs and L-PPE:O (R=0.075), but not non-anionic 
surfaces, induced MP-depleted plasma coagulation that was comparable to PPP and MP-enriched 
PPP.  Abbreviations: MA: maximal amplitude; R: clotting time; (alpha): degrees of inflection 
of the TEG curve where higher angles reflect higher clot velocity; CYR: Cyrolite® TEG cups 
and pins; LB: latex beads; H: HMDSO-coated TEG cups and pins; CB*: carboxylic acid 
modified latex beads are uncharged at neutral pH; GB: glass microbeads HA: hydroxyapatite 
nanoparticles; PPEO: L-PPE:O-coated TEG cups and pins; MP: Microparticles; PPP: platelet-















Figure 6. TEG traces of burst coagulation of MP-depleted plasma including (A) MP-depleted 
plasma and (B) FXII-depleted plasma(A) All 3 types of anionic surface induced explosive 
thrombin generation in MP-depleted plasma including L-PPE:O at increasing [COO] (in at%), 
glass microbeads, and HA NPs. (B) FXIa was necessary and sufficient to induce burst 
coagulation in a dose-dependent manner of FXII-depleted, MP-depleted plasma with no effect of 















Figure 7. ESEM high-magnification imaging of PPP clots (A-C) and MP-depleted plasma clots 
(D-F) formed in the presence of glass microbeads showed a similar fibrin clot structure. Both 
thick and thin branched fibrin strands adhered to the glass beads. Small arrows in Panels A & C 
indicate glass beads; arrow in panel C indicates aggregated spherical structures near the top of 



































Table 1. Materials tested for pro-coagulant activity in PPP or MP-depleted plasma. 
Surface tested Supplier Character Surface type 
Cyrolite®     Haemscope hydrophobic             bare TEG cup and pin 
PP-HMDSO                 In-house hydrophobic TEG cup and pin surface 
nanocoating; glass bead coating 
L-PPE:O               In-house hydrophilic/anionic 
0, 4.4, or 6.8 at% 
[COO⁻ ]  
TEG cup and pin surface 
nanocoating 
Latex (polystyrene) beads Sigma-Aldrich hydrophobic  10 µm diameter beads 
Carboxylated CML latex beads* Life Sciences hydrophobic/hydrophilic 10 µm diameter beads  
Glass microbeads    
             
Matweb hydrophilic/anionic    10 µm diameter beads 
HA nanoparticles (MIV 
CTAB/IGEPAL-based crystals) 
In-house hydrophilic/anionic  
(2.03 Ca/P) 
41 nm length, 9 nm diameter 
nano-cylinders 
 * According to the COA: 6.8 x 108 COOH/bead with a hydrophilic surface at neutral pH but COOH is fully charged 

















Table 2. Parameters used to deposit L-PPE:O and PP-HMDSO on TEG cups and pins by 













Cyrolite® -- -- -- -- 77±1 
L-PPE:O 
R=0.025 
Ethylene - 20 
Oxygen - 0.5* 
10 600 20 64±1 
L-PPE:O 
R=0.050 
Ethylene - 20 
Oxygen - 1.0* 
10 600 40 51±2 
L-PPE:O 
R=0.075 
Ethylene - 20 
Oxygen - 1.5* 
10 600 60 45±1 
PP-HMDSO HMDSO - 20 50 60 2 98±2 
Abbreviations: sccm: standard cubic centimeters per minute; *produced by a mixture of 10% O2 and 90% Ar, 
















Table 3. Elemental composition of Cyrolite® and L-PPE:O deposits with different oxygen 






Cyrolite 77.7±2.5 22.3±2.5 
R = 0.025 85.7±0.9 14.3±0.9 
R = 0.050 76.9±1.9 24.4±0.8 
R = 0.075 70.2±0.8 29.8±0.8 
 
Table 4. C1s- and O1s-deconvolutions of L-PPE:O deposits for R= 0.025, R= 0.050, and R= 
0.075, component concentrations, possible chemical bonds and binding energies (BE)  
Element C1s O1s 
Peak label A B C D E A B 
Peak BE 
(eV) 








C-C C-COOR C-OR C=O COOR O=C O-C 
R= 0.025 
(at.%) 
71.0±1.3 ----- 9.8±0.1 4.5±0.4 ------ 5.2±0.6 9.6±0.3 
R= 0.05 
(at.%) 
50.6±2.0 4.4±0.2 11.7±1.1 6.2±0.3 4.4±0.2 14.0±0.6 10.7±0.2 
R= 0.075 
(at.%) 
36.5±0.9 6.8±0.4 12.7±0.5 6.8±0.2 6.8±0.4 17.9±0.2 12.6±0.1 















Table 5. Elemental composition of 500 µm diameter glass beads, unmodified and after 
coating with PP-HMDSO 
Unmodified glass 
beads (at. %) 
PP-HMDSO coated 
glass beads (at. %) 
[Si]=16 [SiO2]=1.57 
[O]=45 [SiO1.5C]=5.5 
[C]=37 [SiOC2]=5.5 
[Ca]=1 [SiO0.5C3]=5.5 
[Na]=0.5  
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